Enterovirus 3C Protease Compounds for Improved Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective therapeutic options for enterovirus-related diseases, particularly due to the low bioavailability of existing 3C protease inhibitors like AG7088, and no specific medicines are available for treating severe conditions caused by enteroviruses such as rhinovirus, poliovirus, coxsackievirus, and echovirus.
Innovation Solution
Development of compounds ST-0101 and ST-0102, which can reversibly bind to the cysteine residue (C147) of the 3C protease in enteroviruses, providing significant inhibitory activity against multiple enterovirus serotypes, including rhinovirus, poliovirus, coxsackievirus, and echovirus, and are used in pharmaceutical compositions to treat intestinal-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AG7088 is used as a 3C protease inhibitor, then antiviral activity against enteroviruses is achieved, but bioavailability is low
Solution Approach 1:
The patent modifies the chemical structure of AG7088 by changing parameters such as introducing a carbonyl group at the 2-position of the pyridine ring and adjusting substituents at positions 4 and 5. These structural parameter changes result in improved bioavailability while maintaining antiviral activity against enteroviruses.
Solution Approach 2:
The patent creates a composite molecular structure by combining the core pyridine ring of AG7088 with additional functional groups and substituents (such as carbonyl groups, fluorine atoms, and aromatic rings). This composite structure enhances both the antiviral efficacy and bioavailability properties of the inhibitor.
2Adaptability or versatility
If no specific medicine is developed for enterovirus infections, then treatment options remain limited, but the complexity of developing new medicines increases
Solution Approach 1:
The patent designs a universal 3C protease inhibitor structure that can effectively target multiple enterovirus serotypes (including rhinovirus, poliovirus, coxsackievirus, and echovirus) through a single compound class. This multi-functional approach expands treatment options without requiring separate drugs for each virus type, thereby reducing the overall complexity of developing targeted therapies.
3Reliability
If 3C protease inhibitors are developed, then antiviral efficacy is improved, but side effects against mammalian proteases may occur
Solution Approach 1:
The patent introduces a carbonyl group at the 2-position of the pyridine ring, creating a local structural feature that enhances selectivity for the 3C protease active site. This local modification allows the inhibitor to bind specifically to the viral protease while minimizing interaction with mammalian proteases, thereby reducing side effects.
Solution Approach 2:
The patent leverages the existing binding affinity of AG7088 for the 3C protease and refines it through structural modifications. By optimizing the interaction between the inhibitor and the viral protease binding pocket, the patent converts the potential non-specific binding issue into a benefit, achieving high selectivity and reducing harmful side effects on mammalian systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ST-0101 and ST-0102 effectively inhibit 3C protease activities, offering a broad-spectrum treatment for enterovirus-related diseases, including severe conditions like asthma exacerbations and paralysis, and can be used in pharmaceutical compositions to treat intestinal-related diseases.
Implementation Method 1
ST-0101 and ST-0102 may reversibly bind to a cysteine residue (C147) of a HRV 3C protease
Data Source
AI summary
Disclosed are a compound and an application thereof in the preparation of a medicine for treating enterovirus-related diseases. The compound is the compound represented below by formula I, and can significantly inhibit the 3C protease activity of various enteroviruses. At present, no specific medicine aimed at human enteroviruses has been approved to come to market, and the use of the solution of the present invention can compensate for the insufficiencies of the prior art.